Wall Street analyst estimates for Adaptimmune Therapeutics plc (ADAP): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 4 |
| Sell | 3 |
| Strong Sell | 0 |
| Total analysts | 16 |
| Avg rating (1-5) | 0.38 |
Valuation Ratios
| Price / Book | -0.18 |
| EV / EBITDA | -1.42 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.7M | $14.2M | $37.8M | $59.5M | $1.1M | $4.0M | $6.1M | $27.1M | $60.3M | $178.0M |
| Cost of Revenue | 0 | 0 | 0 | 0 | $97.5M | $91.6M | $111.1M | $127.7M | $9.9M | $70000 |
| Gross Profit | $10.7M | $14.2M | $37.8M | $59.5M | -$96.4M | -$87.6M | -$104.9M | -$100.6M | $50.4M | $178.0M |
| Research & Development | $23.2M | $63.8M | $87.4M | $98.3M | $97.5M | $91.6M | $111.1M | $127.7M | $126.5M | $149.1M |
| Selling, General & Admin | $11.3M | $23.2M | $31.1M | $43.6M | $43.4M | $45.8M | $57.3M | $63.4M | $71.8M | $81.3M |
| Operating Expenses | $33.8M | $87.0M | $118.5M | $141.9M | $140.9M | $137.4M | $168.4M | $191.1M | $188.4M | $246.7M |
| Operating Income | -$23.1M | -$72.8M | -$80.7M | -$82.4M | -$139.8M | -$133.4M | -$162.2M | -$164.0M | -$138.0M | -$68.8M |
| EBITDA | -$23.8M | -$69.5M | -$75.2M | -$74.6M | -$131.8M | -$125.8M | -$155.7M | -$155.6M | -$128.2M | -$52.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $3.3M |
| Pre-tax Income | -$23.7M | -$70.7M | -$69.7M | -$95.0M | -$136.9M | -$129.9M | -$157.3M | -$163.0M | -$112.5M | -$67.3M |
| Income Tax | -$2.1M | $892000 | $451000 | $497000 | $242000 | $162000 | $791000 | $2.5M | $1.3M | $3.6M |
| Net Income | -$21.6M | -$71.6M | -$70.1M | -$95.5M | -$137.2M | -$130.1M | -$158.1M | -$165.5M | -$113.9M | -$70.8M |
| EPS | $-0.60 | $-1.02 | $-0.78 | $-0.96 | $-1.32 | $-0.90 | $-1.02 | $-1.02 | $-0.57 | $-0.28 |
| EPS (Diluted) | $-0.60 | $-1.02 | $-0.78 | $-0.96 | $-1.32 | $-0.90 | $-1.02 | $-1.02 | $-0.57 | $-0.28 |
| Shares Outstanding (Diluted) | $35.8M | $70.8M | $87.9M | $97.4M | $105.0M | $142.5M | $155.8M | $161.2M | $201.1M | $252.3M |
Price
| Price | $0.05 |
| Market Cap | $75M |
| Exchange | NASDAQ |
| Country | GB |
Related companies: ANL · APLM · BLRX · ERNA · GOVX · LNAI · LPCN
Explore sector: Healthcare · Biotechnology
More sections of ADAP: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks